This is a Validated Antibody Database (VAD) review about human SLAMF7, based on 12 published articles (read how Labome selects the articles), using SLAMF7 antibody in all methods. It is aimed to help Labome visitors find the most suited SLAMF7 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
SLAMF7 synonym: 19A; CD319; CRACC; CS1; SLAM family member 7; 19A24 protein; CD2 subset 1; CD2-like receptor activating cytotoxic cells; membrane protein FOAP-12; novel LY9 (lymphocyte antigen 9) like protein; protein 19A
BioLegend
mouse monoclonal (162.1) |
| In order to detail MAIT cell responses to various microorganisms and cytokines, BioLegend SLAMF7 antibody (BioLegend, 162.1) was used in flow cytometry on human samples (fig 4h). Proc Natl Acad Sci U S A (2017) ncbi |
mouse monoclonal (162.1) |
| In order to map the lineage of human dendritic cells, BioLegend SLAMF7 antibody (BioLegend, 162,1) was used in flow cytometry on human samples (fig s14b). Science (2017) ncbi |
mouse monoclonal (162.1) |
| In order to investigate the function of SLAMF in phagocytosis of haematopoietic tumour cells, BioLegend SLAMF7 antibody (Biolegend, 162.1) was used in flow cytometry on human samples (fig e6b) and in flow cytometry on mouse samples (fig 3d). Nature (2017) ncbi |
mouse monoclonal (162.1) |
| In order to determine the function of the SLAM family of proteins in natural killer cells, BioLegend SLAMF7 antibody (BioLegend, 162.1) was used in flow cytometry on mouse samples (fig 8a). J Exp Med (2016) ncbi |
mouse monoclonal (162.1) |
| In order to study the effect of anti-SLAMF6 antibody and ibrutinib on chronic lymphocytic leukemia cells, BioLegend SLAMF7 antibody (biolegend, 162.1) was used in flow cytometry on human samples (fig 1d). Oncotarget (2016) ncbi |
mouse monoclonal (162.1) |
| In order to screen for and assess myeloma plasma cell markers, BioLegend SLAMF7 antibody (Biolegend, 162.1) was used in flow cytometry on human samples (fig 2a). Blood (2014) ncbi |
R&D Systems
rat monoclonal (520914) |
| In order to examine natural killer T cell development in mice deficient for SLAM family receptors, R&D Systems SLAMF7 antibody (R&D Systems, 520914) was used in flow cytometry on mouse samples (fig 1). J Exp Med (2017) ncbi |
mouse monoclonal (235614) |
| R&D Systems SLAMF7 antibody (R&D, MAB1906) was used in ELISA on human samples at 15 ug/ml. AAPS J (2016) ncbi |
rat monoclonal (520914) |
| In order to study the effect of anti-SLAMF6 antibody and ibrutinib on chronic lymphocytic leukemia cells, R&D Systems SLAMF7 antibody (R&D, 520914) was used in flow cytometry on mouse samples (fig 6c). Oncotarget (2016) ncbi |
mouse monoclonal (235614) |
| In order to find cell-surface markers specific to human neutrophils, R&D Systems SLAMF7 antibody (R&D Systems, FAB1906P) was used in flow cytometry on human samples (fig st1). Exp Cell Res (2016) ncbi |
mouse monoclonal (235614) |
| In order to measure the expression of antigens on malignant human plasma cells that have exhibited promise in targeted cancer therapy, R&D Systems SLAMF7 antibody (R&D Systems, 235614) was used in flow cytometry on human samples (fig 1c). Cytometry B Clin Cytom (2017) ncbi |
Invitrogen
mouse monoclonal (162) | In order to identify ABCA1 as a mycobacterial host-restriction factor, Invitrogen SLAMF7 antibody (eBiosciences, 162) was used . Front Microbiol (2016) ncbi | |
mouse monoclonal (162) | In order to compare the use of CD229, CD54, and CD319 expression for the identification of normal and aberrant plasma cells, Invitrogen SLAMF7 antibody (eBioscience, 162) was used . Cytometry B Clin Cytom (2016) ncbi |
Bio-Rad
mouse monoclonal (162) |
| In order to compare the use of CD229, CD54, and CD319 expression for the identification of normal and aberrant plasma cells, Bio-Rad SLAMF7 antibody (ABD SEROTEC, 162) was used in flow cytometry on human samples (tbl 1). Cytometry B Clin Cytom (2016) ncbi |
Articles Reviewed
contribute
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.
questions and comments